Detalles de la búsqueda
1.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30779529
2.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(12): 1563-1573, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33284113
3.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 392(10142): 123-133, 2018 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29880231
4.
Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Pancreatology
; 19(6): 850-857, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31362865
5.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(7): 789-96, 2016 09 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-27599039
6.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Lancet Oncol
; 16(3): 338-48, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25701170
7.
Pilot study of the implementation of G8 screening tool, Cognitive screening assessment and Chemotherapy Toxicity assessment in older adults with cancer in a Tertiary University Hospital in Ireland.
Ir J Med Sci
; 193(1): 45-50, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37450258
8.
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37399357
9.
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Eur Urol
; 84(5): 449-454, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37500340
10.
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
Lancet Gastroenterol Hepatol
; 8(11): 1015-1027, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37734399
11.
Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Eur Urol Oncol
; 5(2): 225-234, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34244116
12.
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
Eur Urol
; 82(4): 427-439, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35843776
13.
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Br J Cancer
; 115(9): e16, 2016 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-27727233
14.
Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer.
Front Cell Dev Biol
; 9: 605686, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33718350
15.
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study.
Ther Adv Med Oncol
; 13: 17588359211042691, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34512801
16.
Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide.
Sci Rep
; 9(1): 10739, 2019 07 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31341219
17.
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Eur Urol
; 85(2): e58-e59, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38071169
18.
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Eur Urol
; 84(5): e123-e124, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37666734
19.
Circular RNAs: Biogenesis, Function and Role in Human Diseases.
Front Mol Biosci
; 4: 38, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634583
20.
Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
J Radiosurg SBRT
; 5(1): 43-53, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-29296462